RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Friedreich Ataxia: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Cells heal themselves: gene-edited hematopoietic stem cells restore frataxin deficiency in multiple organs
(19 October 2026)
https://europepmc.org/search?query=Cells%20heal%20themselves%3A%20gene-edited%20hematopoietic%20s
- 2.
Edited HSPCs rescue frataxin deficiency and inflammation-driven multisystemic pathology in Friedreich’s ataxia mice
Sivakumar A et al. (19 October 2026)
https://europepmc.org/search?query=Edited%20HSPCs%20rescue%20frataxin%20deficiency%20and%20inflam
- 3.
Friedreich Ataxia iPSC-derived microglia display an interferon-responsive, antigen-presenting, and inflammasome-associated state with lysosomal biology and extracellular matrix abnormalities
Ye Man Tang et al., Research Square (18 October 2026)
https://doi.org/10.21203/rs.3.rs-11037120/v1
- 4.
Edited HSPCs rescue frataxin deficiency and inflammation-driven multisystemic pathology in Friedreich's ataxia mice.
Sivakumar Anusha et al., The Journal of clinical investigation (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42878077/
- 5.
Cells heal themselves: gene-edited hematopoietic stem cells restore frataxin deficiency in multiple organs.
Osborne Lucy R, The Journal of clinical investigation (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42878081/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
NCT06874010 · Recruiting · Phase 1 / Phase 2 · Design Therapeutics, Inc.
Ages 18 to 65
https://clinicaltrials.gov/study/NCT06874010
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Friedreich Ataxia
Friedreich ataxia is a progressive genetic condition that damages the nervous system and heart, causing loss of coordination, balance problems, and heart disease. It is the most common inherited ataxia. Symptoms usually begin in childhood or adolescence. The first approved treatment, omaveloxolone, reached approval in 2023.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Friedreich Ataxia?
Friedreich ataxia is a progressive genetic condition that damages the nervous system and heart, causing loss of coordination, balance problems, and heart disease. It is the most common inherited ataxia. Symptoms usually begin in childhood or adolescence. The first approved treatment, omaveloxolone, reached approval in 2023.
How many clinical trials are available for Friedreich Ataxia?
RareWays currently indexes 89 clinical trials for Friedreich Ataxia, of which 9 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Friedreich Ataxia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Friedreich Ataxia.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.